Providing iPSCs to a customer

• US 9,213,999 B2
• Filed: 06/12/2009
• Issued: 12/15/2015
• Est. Priority Date: 06/15/2007
• Status: Active Grant

• Current Assignee: Kyoto University
• Original Assignee: Kyoto University
• Inventors: Sakurada, Kazuhiro
• Primary Examiner(s): Crouch, Deborah
• Application Number:
  US12/484,152
• Publication Number:
  US 20090299763A1
• Time in Patent Office: 2,377 Days
• US Class Current: 1/1
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/602 Sox-2
• CPC Class Codes: C12N 2501/603 Oct-3/4
• CPC Class Codes: C12N 2501/604 Klf-4
• CPC Class Codes: C12N 2501/605 Nanog
• CPC Class Codes: C12N 2501/606 c-Myc
• CPC Class Codes: C12N 2501/608 Lin28
• CPC Class Codes: C12N 2502/45 Artificially induced pluripotent stem cells
• CPC Class Codes: C12N 2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2799/027 where the vector is derived from a retrovirus
• CPC Class Codes: C12N 5/0696 Artificially induced pluripotent stem cells, e.g. iPS
• CPC Class Codes: G16H 20/40 relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

The present disclosure features methods relating to conducting a stem cell technology business such as a regenerative medicine business based on induced pluripotent stem cells (iPSCs) and cells differentiated from iPSCs. The present disclosure also provides a database of iPSC-derived cells and methods of using the database for tracking customers and samples, as well as methods for marketing and running the business.

Claims

1. A method for providing mammalian iPSC-derived differentiated cells to a customer, comprising:

(a) expanding mammalian iPSCs and stocking the expanded iPSCs in an iPSC bank, wherein the iPSCs are obtained from a plurality of different iPSCs, each of the iPSCs being derived from a sample of mammalian somatic cells obtained from a donor having a disease or condition or genetically predisposed to a disease or condition;

(b) obtaining criteria from a customer for selection of an iPSC based on one or more of of the diseases or conditions suffered by donor or for which the donor is genetically predisposed;

(c) searching a database comprising sample information for each of the plurality of different iPSCs in an iPSC bank, said different iPSCs having genetic material from different donors, said sample information comprising one or more of said criteria;

(d) identifying suitable iPSCs matching the criteria from the customer in said iPSC bank; and

(e) differentiating a part of the iPSCs stocked in step (a) and identified in step (d) to produce the mammalian iPSC-derived differentiated cells; and

(f) providing the mammalian iPSC-derived differentiated cells to the customer.

2. The method of claim 1, further comprising a step of selecting a desired subpopulation of iPSCs-derived differentiated cells obtained in step (e);

wherein the desired subpopulation is identified by one or more of;

a monoclonal antibody specific to a desired cell type, expression of a reporter gene in a cell type specific manner, negative selection of proliferating cells with the herpes simplex virus thymidine kinase/ganciclovir suicide gene system, and positive selection of cells expressing a bicistronic reporter.

3. The method of claim 1, wherein the iPSCs are differentiated to produce one or more cell types selected from the group consisting of:

neural stem cells, cardiac stem cells, hepatic stem cells, hematopoietic stem cells, ectodermal cells, mesodermal cells, endodermal cells, neurons, oligodendrocytes, astrocytes, motor neurons, fibroblasts, cardiomyocytes, pancreatic progenitor cells, pancreatic beta cells, hepatocytes, myocytes, dopaminergic neurons, adipocytes, chondrocytes, smooth muscle cells, keratinocytes, macrophages, mast cells, melanocytes, osteoblasts, skeletal muscle cells, retinal cells, glial progenitor cells, glial cells, lung progenitor cells and white blood cells.

4. The method of claim 1, wherein the disease or condition is selected from the group consisting of:

a neurodegenerative disorder, a neurological disorder, an eye disease, a mood disorder, a respiratory disease, an auditory disease, a cardiovascular disease, an immunological disorder, a hematological disease, a metabolic disorder, a kidney disease, a proliferative disorder, a genetic disorder, an autoimmune disease, a drug sensitivity condition, a cognitive impairment, depression, deafness, osteoporosis, diabetes, macular degeneration, obesity, Alexander'"'"'s disease, Alper'"'"'s disease, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten disease, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington'"'"'s disease, HIV-associated dementia, Kennedy'"'"'s disease, Krabbe'"'"'s disease, lewy body dementia, Machado-Joseph disease, multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson'"'"'s disease, Pelizaeus-Merzbacher Disease, Pick'"'"'s disease, primary lateral sclerosis, a prion disease, Refsum'"'"'s disease, Sandhoffs disease, Schilder'"'"'s disease, subacute combined degeneration of spinal cord secondary to pernicious anaemia, schizophrenia, spinocerebellar ataxia, spinal muscular atrophy (SMA), Steele-Richardson-Olszewski disease, tabes dorsalis, acquired immune deficiency, leukemia, lymphoma, a hypersensitivity (allergy), severe combined immune deficiency, acute disseminated encephalomyelitis, addison'"'"'s disease, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid, coeliac disease, dermatomyositis, diabetes mellitus type 1, diabetes mellitus type 2, Goodpasture'"'"'s syndrome, Graves'"'"' disease, Guillain-Barre syndrome, Hashimoto'"'"'s disease, idiopathic thrombocytopenic purpura, lupus erythematosus, myasthenia gravis, pemphigus, pernicious anaemia, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, Sjogren'"'"'s syndrome, temporal arthritis, vasculitis, Wegener'"'"'s granulomatosis, aneurysm, angina, arrhythmia, atherosclerosis, cardiomyopathy, calcific aortic valve disease (CAVD), cerebrovascular accident (stroke), cerebrovascular disease, congenital heart disease, congestive heart failure, myocarditis, valve disease coronary, cardiomyopathy, diastolic dysfunction, endocarditis, hypertension, hypertrophic cardiomyopathy, mitral valve prolapse, myocardial infarction, venous thromboembolism, acid lipase disease, amyloidosis, Barth Syndrome, biotinidase deficiency, camitine palmitoyl transferase deficiency type II, central pontine myelinolysis, muscular dystrophy, Farber'"'"'s Disease, glucose-6-phosphate dehydrogenase deficiency, gangliosidoses, trimethylaminuria, Lesch-Nyhan syndrome, lipid storage diseases, metabolic myopathies, methylmalonic aciduria, mitochondrial myopathies, mucopolysaccharidoses, mucolipidoses, mucolipidoses, mucopolysaccharidoses, multiple CoA carboxylase deficiency, nonketotic hyperglycinemia, Pompe disease, propionic acidemia, type I glycogen storage disease, urea cycle disorders, hyperoxaluria, oxalosis, carcinoma, sarcoma, germ cell tumors, blastic tumors, prostate cancer, lung cancer, colorectal cancer, bladder cancer, cutaneous melanoma, breast cancer, endometrial cancer, and ovarian cancer.